文献速递糖尿病

胰腺激肽释放酶对2型糖尿病小鼠糖尿病视网膜病变的保护作用

Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
PubMed 文献 · Diabetologia · 2019-03-05

本研究在KK Cg-Ay/J自发2型糖尿病小鼠和高脂饮食/链脲佐菌素诱导的2型糖尿病小鼠模型中,腹腔注射胰腺激肽释放酶或生理盐水12周,发现胰腺激肽释放酶可改善视网膜病理结构、减少无细胞毛细血管形成和血管渗漏,并减轻氧化应激、炎症和凋亡(p < 0.05),同时增加缓激肽及B1、B2受体水平(p < 0.05)。结论提示胰腺激肽释放酶可能通过激活B1和B2受体抑制氧化应激、炎症和凋亡来保护糖尿病视网膜病变。

要点

  • 胰腺激肽释放酶改善两种2型糖尿病小鼠模型的视网膜病理结构。
  • 该酶减少视网膜无细胞毛细血管形成和血管渗漏(p < 0.05)。
  • 其保护作用可能与激活缓激肽B1/B2受体、抑制氧化应激炎症凋亡相关。

核心结论

  • 胰腺激肽释放酶可通过激活B1和B2受体、抑制氧化应激、炎症和凋亡来保护糖尿病视网膜病变,可能成为新的治疗药物。

研究设计与样本

  • 使用KK Cg-Ay/J自发2型糖尿病小鼠和高脂饮食/链脲佐菌素诱导的2型糖尿病小鼠,以C57BL/6J小鼠为非糖尿病对照。
  • 糖尿病发病后,两种模型分别腹腔注射胰腺激肽释放酶或生理盐水,持续12周。

主要发现

  • 在两种模型中,胰腺激肽释放酶改善视网膜病理结构特征,增加视网膜层厚度,减轻无细胞毛细血管形成和血管渗漏(p < 0.05)。
  • 在两种模型中,胰腺激肽释放酶改善视网膜氧化应激、炎症和凋亡(p < 0.05)。
  • 在两种模型中,胰腺激肽释放酶处理后缓激肽及B1和B2受体水平升高(p < 0.05)。

临床怎么用

  • 胰腺激肽释放酶可能作为糖尿病视网膜病变的潜在治疗选择,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Many studies have shown that tissue kallikrein has effects on diabetic vascular complications such as nephropathy, cardiomyopathy and neuropathy, but its effects on diabetic retinopathy are not fully understood. Here, we investigated the retinoprotective role of exogenous pancreatic kallikrein and studied potential mechanisms of action. METHODS: We used KK Cg-Ay/J (KKAy) mice (a mouse model of spontaneous type 2 diabetes) and mice with high-fat diet/streptozotocin (STZ)-induced type 2 diabetes as our models. After the onset of diabetes, both types of mice were injected intraperitoneally with either pancreatic kallikrein (KKAy + pancreatic kallikrein and STZ + pancreatic kallikrein groups) or saline (KKAy + saline and STZ + saline groups) for 12 weeks. C57BL/6J mice were used as non-diabetic controls for both models. We analysed pathological changes in the retina; evaluated the effects of pancreatic kallikrein on retinal oxidative stress, inflammation and apoptosis; and measured the levels of bradykinin and B1 and B2 receptors in both models. RESULTS: In both models, pancreatic kallikrein improved pathological structural features of the retina, increasing the thickness of retinal layers, and attenuated retinal acellular capillary formation and vascular leakage (p < 0.05). Furthermore, pancreatic kallikrein ameliorated retinal oxidative stress, inflammation and apoptosis in both models (p < 0.05). We also found that the levels of bradykinin and B1 and B2 receptors were increased after pancreatic kallikrein in both models (p < 0.05). CONCLUSIONS/INTERPRETATION: Pancreatic kallikrein can protect against diabetic retinopathy by activating B1 and B2 receptors and inhibiting oxidative stress, inflammation and apoptosis. Thus, pancreatic kallikrein may represent a new therapeutic agent for diabetic retinopathy.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Cheng Y, Yu X, Zhang J, et al. Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes. Diabetologia. 2019. PMID: 30838453. doi:10.1007/s00125-019-4838-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。